Montelukast


Generic Medicine Info
Special Precautions
Patient with known aspirin sensitivity (continue avoidance of aspirin or NSAIDs during treatment with montelukast). Not indicated for the treatment of acute asthma attacks, including status asthmaticus. Not recommended as monotherapy in patients with moderate persistent asthma. Avoid abrupt substitution to inhaled or oral corticosteroids. Children. Pregnancy and lactation. Monitoring Parameters Monitor for neuropsychiatric symptoms, including changes in behaviour and suicidal thoughts.
Adverse Reactions
Significant: Neuropsychiatric events (e.g. agitation, depression, hallucinations, suicidal thoughts and behaviour, dream abnormalities, aggressive behaviour or hostility, anxiety, disorientation, disturbance in attention, dysphemia, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, tic, tremor). Rarely, systemic eosinophilia (sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome). Blood and lymphatic system disorders: Rarely, increased bleeding tendency, thrombocytopenia. Cardiac disorders: Rarely, palpitations. Ear and labyrinth disorders: Otitis media. Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting, thirst, dry mouth, dyspepsia. General disorders and administration site conditions: Pyrexia, asthenia, malaise, oedema. Immune system disorders: Hypersensitivity reactions including anaphylaxis. Investigations: Elevated ALT/AST levels. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, muscle cramps. Nervous system disorders: Headache, dizziness, drowsiness, paraesthesia, hypoaesthesia, seizure. Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, pharyngitis, cough, influenza, rhinorrhea, sinusitis, epistaxis. Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria, bruising.
Drug Interactions
Decreased plasma concentration with CYP inducers (e.g. phenobarbital, phenytoin, rifampicin). Increased systemic exposure with gemfibrozil.
CIMS Class
Antiasthmatic & COPD Preparations / Antihistamines & Antiallergics
ATC Classification
R03DC03 - montelukast ; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on montelukast from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in